๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

โœ Scribed by C.-Y. Peng; H.-C. Lai; Y.-F. Li; W.-P. Su; P.-H. Chuang; J.-T. Kao

Book ID
108606587
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
274 KB
Volume
35
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Hepatitis B virus surface antigen levels
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
โœ Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K. K. La ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 748 KB

Bristol-Myers Squibb, Gilead, and Novartis. He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on th

Early on-treatment prediction of respons
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
โœ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 189 KB ๐Ÿ‘ 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.